Chapter 6 Folding Considerations for Therapeutic Protein Formulations

Progress in Nucleic Acid Research and Molecular Biology

Volumn 83, Issue , 2008, Pages 255-270

  Korotchkina, Lioubov G ^a   Ramani, Karthik ^b   Balu iyer, Sathy V ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b Biocon Limited   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMIMETIC MATERIAL; PROTEIN;

ANIMAL; ARTICLE; CHEMISTRY; DRUG DEVELOPMENT; GENETICS; HUMAN; METABOLISM; PROTEIN DENATURATION; PROTEIN FOLDING;

ANIMALS; BIOMIMETIC MATERIALS; DRUG DISCOVERY; HUMANS; PROTEIN DENATURATION; PROTEIN FOLDING; PROTEINS;

EID: 58749091115     PISSN: 00796603     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6603(08)00606-5     Document Type: Review

References (36)

1. Leader B., Baca Q.J., and Golan D.E. Protein therapeutics: A summary and pharmacological classification. Nat. Rev. Drug Discov. 7 (2008) 21-39
2. Manning M.C., Patel K., and Borchardt R.T. Stability of protein pharmaceuticals. Pharm. Res. 6 (1989) 903-918
3. Rosenberg A.S. Effect of protein aggregates: An immunologic perspective. Aaps J. 8 (2006) E501-E507
4. Jacquemin M.G., and Saint-Remy J.M. Factor VIII immunogenicity. Haemophilia 4 (1998) 552-557
5. Lollar P., Healey J.F., Barrow R.T., and Parker E.T. Factor VIII inhibitors. Adv. Exp. Med. Biol. 489 (2001) 65-73
6. McKoy J.M., Stonecash R.E., Cournoyer D., Rossert J., Nissenson A.R., Raisch D.W., Casadevall N., and Bennett C.L. Epoetin-associated pure red cell aplasia: Past, present, and future considerations. Transfusion 48 (2008) 1754-1762
7. Wang W. Protein aggregation and its inhibition in biopharmaceutics. Intern. J. Pharm. 289 (2005) 1-30
8. Krishnamurthy R., and Manning M.C. The stability factor: Importance in formulation development. Curr. Pharm. Biotechnol. 3 (2002) 361-371
9. Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Intern. J. Pharm. 185 (1999) 129-188
10. Chi E.Y., Krishnan S., Randolph T.W., and Carpenter J.F. Physical stability of proteins in aqueous solution: Mechanism and driving forces in nonnative protein aggregation. Pharm. Res. 20 (2003) 1325-1336
11. Kendrick B.S., Carpenter J.F., Cleland J.L., and Randolph T.W. A transient expansion of the native state precedes aggregation of recombinant human interferon-gamma. Proc. Natl. Acad. Sci. USA 95 (1998) 14142-14146
12. Krishnan S., Chi E.Y., Webb J.N., Chang B.S., Shan D., Goldenberg M., Manning M.C., Randolph T.W., and Carpenter J.F. Aggregation of granulocyte colony stimulating factor under physiological conditions: Characterization and thermodynamic inhibition. Biochemistry 41 (2002) 6422-6431
13. Grillo A.O., Edwards K.L., Kashi R.S., Shipley K.M., Hu L., Besman M.J., and Middaugh C.R. Conformational origin of the aggregation of recombinant human factor VIII. Biochemistry 40 (2001) 586-595
14. Ramani K., Purohit V.S., Miclea R.D., Middaugh C.R., and Balasubramanian S.V. Lipid binding region (2303-2332) is involved in aggregation of recombinant human FVIII (rFVIII). J. Pharm. Sci. 94 (2005) 1288-1299
15. Chi E.Y., Krishnan S., Randolph T.W., and Carpenter J.F. Physical stability of proteins in aqueous solution: Mechanism and driving forces in nonnative protein aggregation. Pharm. Res. 20 (2003) 1325-1336
16. Lumry R., and Eyring H. Conformation changes of proteins. J. Phys. Chem. 58 (1954) 110-120
17. Sanchez-Ruiz J.M., Lopez-Lacomba J.L., Cortijo M., and Mateo P.L. Differential scanning calorimetry of the irreversible thermal denaturation of thermolysin. Biochemistry 27 (1988) 1648-1652
18. Kendrick B.S., Cleland J.L., Lam X., Nguyen T., Randolph T.W., Manning M.C., and Carpenter J.F. Aggregation of recombinant human interferon gamma: Kinetics and structural transitions. J. Pharm. Sci. 87 (1998) 1069-1076
19. Vermeer A.W., and Norde W. The thermal stability of immunoglobulin: Unfolding and aggregation of a multi-domain protein. Biophys. J. 78 (2000) 394-404
20. Patra A.K., Mukhopadhyay R., Mukhija R., Krishnan A., Garg L.C., and Panda A.K. Optimization of inclusion body solubilization and renaturation of recombinant human growth hormone from Escherichia coli. Protein Expr. Purif. 18 (2000) 182-192
21. Tran-Moseman A., Schauer N., and De Bernardez Clark E. Renaturation of Escherichia coli-derived recombinant human macrophage colony-stimulating factor. Protein Expr. Purif. 16 (1999) 181-189
22. Sahdev S., Khattar S.K., and Saini K.S. Production of active eukaryotic proteins through bacterial expression systems: A review of the existing biotechnology strategies. Mol. Cell. Biochem. 307 (2008) 249-264
23. Harn N., Allan C., Oliver C., and Middaugh C.R. Highly concentrated monoclonal antibody solutions: Direct analysis of physical structure and thermal stability. J. Pharm. Sci. 96 (2007) 532-546
24. Tsai P.K., Volkin D.B., Dabora J.M., Thompson K.C., Bruner M.W., Gress J.O., Matuszewska B., Keogan M., Bondi J.V., and Middaugh C.R. Formulation design of acidic fibroblast growth factor. Pharm. Res. 10 (1993) 649-659
25. Purohit V.S., Ramani K., Sarkar R., Kazazian Jr. H.H., and Balasubramanian S.V. Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-o-phospho-l-serine complex. J. Biol. Chem. 280 (2005) 17593-17600
26. Miclea R.D., Purohit V.S., and Balu-Iyer S.V. o-phospho-l-serine, multi-functional excipient for B domain deleted recombinant factor VIII. Aaps J. 9 (2007) E251-E259
27. Pikal M.J. Freeze-drying of proteins. In: Cleland J.L., and Langer R. (Eds). Formulation and Delivery of Proteins and Peptides. ACS Symposium Series (1994) 120-133
28. Kozlowski A., Charles S.A., and Harris J.M. Development of pegylated interferons for the treatment of chronic hepatitis C. Biodrugs 15 (2001) 419-429
29. Balasubramanian S., Straubinger R.M., Ramani K., Besman M., and Kashi R. Method of complexing a protein by the use of a dispersed system and proteins thereof (2006) (WO/2006/002195)
30. Roger S.D. Biosimilars: How similar or dissimilar are they. Nephrology 11 (2006) 341-346
31. Kuhlmann M., and Covic A. The protein science of biosimilars. Nephrol. Dial. Transplant. 21 Suppl. 5 (2006) v4-v8
32. Shen B.W., Spiegel P.C., Chang C.H., Huh J.W., Lee J.S., Kim J., Kim Y.H., and Stoddard B.L. The tertiary structure and domain organization of coagulation factor VIII. Blood 111 (2008) 1240-1247
33. Stoilova-McPhie S., Villoutreix B.O., Mertens K., Kemball-Cook G., and Holzenburg A. 3-Dimensional structure of membrane-bound coagulation factor VIII: Modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography. Blood 99 (2002) 1215-1223
34. Ramani K., Purohit V., Middaugh C.R., and Balasubramanian S.V. Aggregation kinetics of recombinant human FVIII (rFVIII). J. Pharm. Sci. 94 (2005) 2023-2029
35. Andrews J.M., and Roberts C.J. A Lumry-Eyring nucleated polymerization model of protein aggregation kinetics: 1. Aggregation with pre-equilibrated unfolding. J. Phys. Chem. B Condensed Matter Mater. Surfaces Interfaces Biophys. 111 (2007) 7897-7913
36. Carpenter J.F., Randolph T.W., Jiskoot W., Crommelin D.J., Middaugh C.R., Winter G., Fan Y.-X., Kirshner S., Verthelyi D., Kozlowski S., Clouse K.A., Swann P.G., et al. Overlooking subvisible particles in therapeutic protein products: Gaps that may compromise product quality. J. Pharm. Sci. (2008) DOI: 10.1002/jps.21530